New leukemia drug candidate undergoes heart safety check
Knowledge-focused
Recruiting now
This early-stage trial is testing whether a single dose of XY0206 tablets affects the heart's electrical activity (QTc interval) in 45 healthy Chinese adults. Participants are randomly assigned to receive XY0206, a placebo, or an active control (moxifloxacin). The study lasts 3 d…
Phase: PHASE1 • Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:01 UTC